Edition:
United States

Fate Therapeutics Inc (FATE.OQ)

FATE.OQ on NASDAQ Stock Exchange Global Market

3.00USD
17 Jan 2017
Change (% chg)

$-0.05 (-1.64%)
Prev Close
$3.05
Open
$3.03
Day's High
$3.08
Day's Low
$3.00
Volume
12,411
Avg. Vol
31,588
52-wk High
$3.81
52-wk Low
$1.46

FATE.OQ

Chart for FATE.OQ

About

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from... (more)

Overall

Beta: --
Market Cap(Mil.): $104.15
Shares Outstanding(Mil.): 34.15
Dividend: --
Yield (%): --

Financials

  FATE.OQ Industry Sector
P/E (TTM): -- 45.90 30.76
EPS (TTM): -1.11 -- --
ROI: -66.99 -1.00 14.82
ROE: -93.70 -0.71 16.24

BRIEF-Fate Therapeutics files for resale of up to 20.9 mln shares of co's common stock by selling stockholders - SEC filing

* Fate Therapeutics Inc - files for resale of up to 20.9 million shares of co's common stock by the selling stockholders - SEC filing Source text: (http://bit.ly/2jkJRHz) Further company coverage:

Jan 06 2017

BRIEF-Fate Therapeutics reports private financing

* Says entered into a definitive securities purchase agreement with certain institutional and other accredited investors

Nov 22 2016

BRIEF-Fate Therapeutics reports Q3 2016 financial results

* Fate Therapeutics reports third quarter 2016 financial results

Nov 07 2016

BRIEF-Fate Therapeutics issues U.S.patent protecting hematopoietic stem cell

* Fate Therapeutics announces issuance of U.S. patent protecting enhanced hematopoietic stem cell compositions Source text for Eikon: Further company coverage:

Oct 05 2016

BRIEF-Fate Therapeutics receives FDA orphan drug designation for Protmune

* Fate Therapeutics receives FDA orphan drug designation for Protmune in allogeneic hematopoietic cell transplantation Source text for Eikon: Further company coverage:

Sep 26 2016

BRIEF-Fate therapeutics files for offer, sale of up to 5.25 mln shares of co's common stock by selling stockholders

* Files for offer and sale of up to 5.25 million shares of co's common stock by selling stockholders - sec filing Source text (http://bit.ly/2cEgfzm) Further company coverage:

Sep 12 2016

BRIEF-Fate Therapeutics reports Q2 2016 financial results

* Fate Therapeutics reports second quarter 2016 financial results

Aug 08 2016

BRIEF-Fate Therapeutics receives patent for human induced pluripotent cells

* Fate Therapeutics announces issuance of U.S. Patent on compositions of human induced pluripotent cells

Jul 26 2016

Earnings vs. Estimates